This article originally appeared on our sister site, Ophthalmology Times Europe®.
Nanoscope Therapeutics’ MCO-010 (sonpiretigene isteparvovec), an investigational ambient-light activatable multi-characteristic opsin (MCO) gene therapy, showed the ability to restore vision in patients with retinitis pigmentosa (RP) in clinical data published Molecular Therapy.1
In the paper, which is entitled “A synthetic opsin restores vision in patients with severe retinal degeneration,” MCO-010 was described. A synthetic opsin with broad spectral sensitivity administered via intravitreal injection, Synthopsin-MCO-010 includes a promoter to specifically target ON-bipolar cells. In preclinical research, Synthopsin-MCO-010 demonstrated the ability to restore the visual behavior in RP mouse models, according to the authors. In the…